Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
Autism Symptoms in Kids
FDA to Approve New Use of Cancer Drug for Autism Symptoms in Kids
Hanmi
Hanmi Reveals Promising Preclinical Results for Obesity Drug
Astellas’ Izervay
Astellas’ Izervay gains conditional approval in Japan for GA treatment
Pfizer buys monthly GLP-1RA
Pfizer buys monthly GLP-1RA developer Metsera for up to $4.9bn
Sanofi's
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
Barth syndrome
FDA clears first treatment for rare male genetic disorder, Barth syndrome
Lupin’s Pune
US FDA flags four observations at Lupin’s Pune biotech facility
Zurzuvae
Biogen’s Zurzuvae approved as first postpartum depression drug in Europe
Antengene
Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
Moderna
Moderna, Alnylam resolve patent litigation over COVID-19 vaccine delivery tech
Eli Lilly
Eli Lilly picks Virginia for $5bn drug manufacturing plant
Modus
Modus data on sevuparin for CKD to be presented at global GAG symposium
1
2
3
4
5
